BioCentury | Dec 6, 2010
Company News

HemaQuest management update

...CEO and a director; and Tamara Seymour as CFO; all of whom formerly served at Favrille Inc....
BioCentury | Dec 4, 2010
Company News

HemaQuest names Longenecker CEO

...Longenecker as president, CEO and a director. Longenecker is the former president and CEO of Favrille Inc....
...hired Richard Ghalie as CMO and Tamara Seymour as CFO, both of whom served at Favrille...
BioCentury | Nov 17, 2008
Company News

Favrille, MyMedicalRecords.com Inc. deal

...the combined company, and Favrille will own 29%. The remaining 7% will be issued to Favrille's...
...common stock. The deal is expected to close by year end. After a June restructuring, Favrille's...
...Favrille said it would like to sell or license the antibodies (see BioCentury, June 2). Favrille Inc....
BioCentury | Sep 29, 2008
Company News

Lpath management update

...Business: Cancer Hired: John Bender as SVP of R&D, formerly SVP of clinical research at Favrille...
BioCentury | Jul 14, 2008
Analyst Picks & Changes

Analyst picks & changes

...is expected to start Phase III testing this half to treat medullary thyroid cancer (MTC). Favrille...
BioCentury | Jul 7, 2008
Finance

2Q approvals

...E2007) to treat Parkinson’s disease (PD) after the compound failed in a Phase III study Favrille...
BioCentury | Jul 7, 2008
Finance

Restructuring watch

...expects to reduce expenses by about $4M for 2008 and about $10M annually thereafter 5/29/08 Favrille...
BioCentury | Jul 7, 2008
Finance

Glass half empty

...GBM) (see BioCentury, June 9 & April 21) . The worst micro-cap failure came for Favrille Inc....
...NASDAQ:AVAN), Needham, Mass. Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Elan Corp. plc (NYSE:ELN), Dublin, Ireland Favrille Inc....
BioCentury | Jun 16, 2008
Analyst Picks & Changes

Analyst picks & changes

...trial. Nevertheless, McCarthy said the high-risk program is a potential blockbuster. He expects data mid-year. Favrille...
BioCentury | Jun 2, 2008
Clinical News

Specifid mitumprotimut-T: Phase III data

...South San Francisco, Calif.), Biogen Idec Inc. (NASDAQ:BIIB, Cambridge, Mass.) and Roche (SWX:ROG, Basel, Switzerland). Favrille Inc....
Items per page:
1 - 10 of 98
BioCentury | Dec 6, 2010
Company News

HemaQuest management update

...CEO and a director; and Tamara Seymour as CFO; all of whom formerly served at Favrille Inc....
BioCentury | Dec 4, 2010
Company News

HemaQuest names Longenecker CEO

...Longenecker as president, CEO and a director. Longenecker is the former president and CEO of Favrille Inc....
...hired Richard Ghalie as CMO and Tamara Seymour as CFO, both of whom served at Favrille...
BioCentury | Nov 17, 2008
Company News

Favrille, MyMedicalRecords.com Inc. deal

...the combined company, and Favrille will own 29%. The remaining 7% will be issued to Favrille's...
...common stock. The deal is expected to close by year end. After a June restructuring, Favrille's...
...Favrille said it would like to sell or license the antibodies (see BioCentury, June 2). Favrille Inc....
BioCentury | Sep 29, 2008
Company News

Lpath management update

...Business: Cancer Hired: John Bender as SVP of R&D, formerly SVP of clinical research at Favrille...
BioCentury | Jul 14, 2008
Analyst Picks & Changes

Analyst picks & changes

...is expected to start Phase III testing this half to treat medullary thyroid cancer (MTC). Favrille...
BioCentury | Jul 7, 2008
Finance

2Q approvals

...E2007) to treat Parkinson’s disease (PD) after the compound failed in a Phase III study Favrille...
BioCentury | Jul 7, 2008
Finance

Restructuring watch

...expects to reduce expenses by about $4M for 2008 and about $10M annually thereafter 5/29/08 Favrille...
BioCentury | Jul 7, 2008
Finance

Glass half empty

...GBM) (see BioCentury, June 9 & April 21) . The worst micro-cap failure came for Favrille Inc....
...NASDAQ:AVAN), Needham, Mass. Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Elan Corp. plc (NYSE:ELN), Dublin, Ireland Favrille Inc....
BioCentury | Jun 16, 2008
Analyst Picks & Changes

Analyst picks & changes

...trial. Nevertheless, McCarthy said the high-risk program is a potential blockbuster. He expects data mid-year. Favrille...
BioCentury | Jun 2, 2008
Clinical News

Specifid mitumprotimut-T: Phase III data

...South San Francisco, Calif.), Biogen Idec Inc. (NASDAQ:BIIB, Cambridge, Mass.) and Roche (SWX:ROG, Basel, Switzerland). Favrille Inc....
Items per page:
1 - 10 of 98